Search clinical trials for: GS-9669

Total 555 results

Gene Signal SAS
Moorfields Eye Hospital NHS Foundation Trust; Johannes Gutenberg University... and other collaborators

Unknown

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG (STRONG)

Neovascular Glaucoma | Ischaemic Central Retinal Vein Occlusion
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection (ASTRAL-5)

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

Hepatitis C Virus Infection

United States, Taiwan, Belgium, Germany, Italy
Gilead Sciences

Completed

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

Chronic HBV Infection

United States, New Zealand
Jianfeng Xie

Unknown

Shenfu Injection Improves Arterial Vascular Reactivity

Septic Shock | Shenfu | Vascular Reactivity
Chonbuk National University Hospital

Completed

Effects of GS-3K8 and GINst15 on Acute Respiratory Illness

Acute Respiratory Infection

Korea, Republic of
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Hepatitis C Virus Infection

Taiwan
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

China, Korea, Republic of, Taiwan
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Puerto Rico
Unity Health Toronto

Active, not recruiting

Incidental Genomics

Cancer

Canada
Gilead Sciences

Recruiting

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

HIV-1-infection

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis (ASTRAL-4)

Hepatitis C Virus Infection

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

Germany, Belgium, United Kingdom, France
MassBiologics
Medarex

Completed

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

Clostridium Infections

United States, Canada
Zhejiang University

Completed

GS Regimen as the First-line Chemotherapy in Chinese Advanced PC Patients

Pancreatic Cancer | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Gilead Sciences

Recruiting

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Israel
Gilead Sciences

Completed

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Hepatitis C Virus Infection

United States, Belgium, Italy, United Kingdom
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

India
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Hepatitis C Virus Infection

United States, New Zealand, Puerto Rico, Australia
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Gilead Sciences

Completed

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Hepatitis B

Korea, Republic of, United States, Canada, Australia, New Zealand
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gilead Sciences
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Hepatitis C | HIV | Liver Fibrosis | HIV/HCV Co-infection

United States
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Hepatitis C Virus Infection

Singapore, Vietnam, China, Thailand, Malaysia
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

Spain
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

Belgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Hepatitis C Virus Infection

United States, Canada, Puerto Rico
Kochi University

Recruiting

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

Pancreatic Adenocarcinoma

Japan
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Respiratory Syncytial Virus Infection

United States, France, Sweden, Korea, Republic of, Switzerland
Gilead Sciences

Completed

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Respiratory Syncytial Virus

Korea, Republic of, Taiwan, Israel, United States, France, Singapore, Sweden, Australia, Canada, United Kingdom, Brazil, Germany, Netherlands, Spain, Switzerland
Gilead Sciences

Withdrawn

A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis | Mucociliary Clearance

Australia
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Gilead Sciences

Completed

Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis

Hepatitis C Virus Infection

United States, France
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Hepatitis C Virus Infection

Spain, Switzerland, United Kingdom
Gilead Sciences

Completed

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus (RSV)

United States, Belgium, Canada, Netherlands, Australia, Germany, United Kingdom, France
Gilead Sciences

Completed

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

Cystic Fibrosis

United States
Gilead Sciences

Completed

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

Healthy Volunteers

United States
Gilead Sciences

Completed

A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences

Completed

Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis

Australia
Gilead Sciences

Completed

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Cystic Fibrosis | Mucociliary Clearance | Airway Hydration

Australia
Gilead Sciences
Novo Nordisk A/S

Active, not recruiting

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

Nonalcoholic Steatohepatitis

United States, Spain, Australia, France, Japan, Puerto Rico, Canada

3

Subscribe